Source comparison
Clinical Applications — Body Recomposition vs Metabolic Correction
Ipamorelin's primary research applications center on preserving lean mass during caloric restriction, accelerating post-injury recovery, and optimizing sleep architecture through GH's nocturnal anabolic window. Studies in geriatric populations (aged 65+) showe
This comparison does not assign a generated winner or score.
- Ipamorelin's primary research applications center on preserving lean mass during caloric restriction, accelerating post-injury recovery, and optimizing sleep architecture through GH's nocturnal anabolic window. Studies in geriatric populations (aged 65+) showed ipamorelin restored GH pulsatility to levels 40–60% of young adults without adverse metabolic effects. It doesn't 'build muscle' directly. GH isn't a primary anabolic hormone for skeletal muscle the way testosterone or IGF-1 are. What ipamorelin does is create an environment where protein synthesis rates stay elevated and proteolysis rates drop during energy deficits. Researchers use it in body recomposition protocols where maintaining strength and muscle mass during fat loss is the goal.
- Tesamorelin has one FDA-approved indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This isn't cosmetic fat loss. It's correction of a metabolic pathology where visceral adipose tissue accumulates dangerously around organs, driving insulin resistance and cardiovascular risk. The pivotal Phase 3 trials (published in The Lancet, 2010) enrolled 806 patients across two studies and found tesamorelin 2mg daily reduced visceral adipose tissue area by 15.2% at 26 weeks versus 4.4% placebo. Measured by CT scan at the L4–L5 level. Subcutaneous fat didn't change. This specificity is the compound's defining feature: it preferentially mobilizes visceral fat through sustained GH-driven lipolysis.
- Our experience with researchers in this space consistently shows the same pattern: ipamorelin gets selected for protocols emphasizing recovery, sleep quality, and lean mass retention. Tesamorelin gets selected when visceral adiposity is the primary endpoint and the research design allows daily dosing. Trying to use ipamorelin for visceral fat reduction or tesamorelin for GH pulsatility restoration mismatches mechanism to outcome.